Last reviewed · How we verify
Lopinavir/ritonavir + zidovudine + lamivudine
Lopinavir/ritonavir + zidovudine + lamivudine is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by Amsterdam UMC, location VUmc. It is currently FDA-approved for HIV-1 infection.
This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.
This combination inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection.
At a glance
| Generic name | Lopinavir/ritonavir + zidovudine + lamivudine |
|---|---|
| Sponsor | Amsterdam UMC, location VUmc |
| Drug class | Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Lopinavir and ritonavir are protease inhibitors that block HIV protease, preventing the maturation of infectious viral particles. Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit the reverse transcriptase enzyme, blocking HIV RNA conversion to DNA. Together, this triple therapy targets multiple steps of the HIV replication cycle.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Lipid abnormalities (elevated cholesterol/triglycerides)
- Hepatotoxicity
- Pancreatitis
- Peripheral neuropathy (from zidovudine)
- Anemia (from zidovudine)
- Lipodystrophy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
- Antiretroviral Regime for Viral Eradication in Newborns (PHASE4)
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (PHASE3)
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lopinavir/ritonavir + zidovudine + lamivudine CI brief — competitive landscape report
- Lopinavir/ritonavir + zidovudine + lamivudine updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI
Frequently asked questions about Lopinavir/ritonavir + zidovudine + lamivudine
What is Lopinavir/ritonavir + zidovudine + lamivudine?
How does Lopinavir/ritonavir + zidovudine + lamivudine work?
What is Lopinavir/ritonavir + zidovudine + lamivudine used for?
Who makes Lopinavir/ritonavir + zidovudine + lamivudine?
What drug class is Lopinavir/ritonavir + zidovudine + lamivudine in?
What development phase is Lopinavir/ritonavir + zidovudine + lamivudine in?
What are the side effects of Lopinavir/ritonavir + zidovudine + lamivudine?
What does Lopinavir/ritonavir + zidovudine + lamivudine target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: Amsterdam UMC, location VUmc — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Compare: Lopinavir/ritonavir + zidovudine + lamivudine vs similar drugs
- Pricing: Lopinavir/ritonavir + zidovudine + lamivudine cost, discount & access